1. Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
- Author
-
Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P, Agladze V, Aliot E, Balabanski T, Blomstrom Lundqvist C, Capucci A, Crijns H, Dahlöf B, Folliguet T, Glikson M, Goethals M, Gulba DC, Ho SY, Klautz RJ, Kose S, McMurray J, PERRONE FILARDI, PASQUALE, Raatikainen P, Salvador MJ, Schalij MJ, Shpektor A, Sousa J, Stepinska J, Uuetoa H, Zamorano JL, Zupan I, European Heart Rhythm Association, European Association for Cardio Thoracic Surgery, ESC Committee for Practice Guidelines, Document Reviewers, Camm, Aj, Kirchhof, P, Lip, Gy, Schotten, U, Savelieva, I, Ernst, S, Van Gelder, Ic, Al Attar, N, Hindricks, G, Prendergast, B, Heidbuchel, H, Alfieri, O, Angelini, A, Atar, D, Colonna, P, De Caterina, R, De Sutter, J, Goette, A, Gorenek, B, Heldal, M, Hohloser, Sh, Kolh, P, Le Heuzey, Jy, Ponikowski, P, Rutten, Fh, Vahanian, A, Auricchio, A, Bax, J, Ceconi, C, Dean, V, Filippatos, G, Funck Brentano, C, Hobbs, R, Kearney, P, Mcdonagh, T, Popescu, Ba, Reiner, Z, Sechtem, U, Sirnes, Pa, Tendera, M, Vardas, Pe, Widimsky, P, Agladze, V, Aliot, E, Balabanski, T, Blomstrom Lundqvist, C, Capucci, A, Crijns, H, Dahlöf, B, Folliguet, T, Glikson, M, Goethals, M, Gulba, Dc, Ho, Sy, Klautz, Rj, Kose, S, Mcmurray, J, PERRONE FILARDI, Pasquale, Raatikainen, P, Salvador, Mj, Schalij, Mj, Shpektor, A, Sousa, J, Stepinska, J, Uuetoa, H, Zamorano, Jl, Zupan, I, European Heart Rhythm, Association, European Association for Cardio Thoracic, Surgery, ESC Committee for Practice, Guideline, Document, Reviewers, Alfieri, Ottavio, Ponikowski, P., Fysiologie, Cardiologie, RS: CARIM School for Cardiovascular Diseases, Camm, A. J, Lip, G, Van Gelder, I. C, Hohloser, S. H, and Le Heuzey, J. Y.
- Subjects
Lung Diseases ,Male ,Rate control ,Heart Valve Diseases ,Management of atrial fibrillation ,Angiotensin-Converting Enzyme Inhibitors ,Comorbidity ,Upstream therapy ,Hyperthyroidism ,law.invention ,Cardiac Resynchronization Therapy ,Electrocardiography ,Ventricular Dysfunction, Left ,Postoperative Complications ,Atrial fibrillation European Society of Cardiology Guidelines Anticoagulation Rate control Rhythm control Upstream therapy Pulmonary vein isolation Left atrial ablation randomized controlled-trial congestive-heart-failure parkinson-white-syndrome cardiac resynchronization therapy angiotensin-converting enzyme polyunsaturated fatty-acids antiarrhythmic-drug therapy long-term survival radiofrequency catheter ablation placebo-controlled trial ,Randomized controlled trial ,Heart Rate ,Pregnancy ,Recurrence ,law ,Prevalence ,Secondary Prevention ,Medicine ,Angioplasty, Balloon, Coronary ,Precision Medicine ,Mineralocorticoid Receptor Antagonists ,Middle Aged ,Congestive-Heart-Failure ,Left atrial ablation ,Primary Prevention ,Stroke ,Catheter Ablation ,Cardiology ,Female ,Rhythm control ,Cardiology and Cardiovascular Medicine ,Risk assessment ,Anti-Arrhythmia Agents ,Sports ,Radiofrequency Catheter Ablation ,Adult ,medicine.medical_specialty ,Point-of-Care Systems ,Angiotensin-Converting Enzyme ,Antiarrhythmic-Drug Therapy ,Placebo-Controlled Trial ,Electric Countershock ,MEDLINE ,Hemorrhage ,Guidelines ,Parkinson-White-Syndrome ,Risk Assessment ,Pulmonary vein isolation ,European Society of Cardiology ,Anticoagulation ,Fibrinolytic Agents ,Thromboembolism ,Internal medicine ,Diabetes Mellitus ,Humans ,Polyunsaturated Fatty-Acids ,International Normalized Ratio ,Acute Coronary Syndrome ,Randomized Controlled-Trial ,Long-Term Survival ,Aged ,Heart Failure ,Intraoperative Care ,business.industry ,Conflict of interest ,Anticoagulants ,Evidence-based medicine ,Cardiomyopathy, Hypertrophic ,Precision medicine ,Atrial fibrillation ,Athletes ,CHA2DS2–VASc score ,Quality of Life ,Wolff-Parkinson-White Syndrome ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,business ,Platelet Aggregation Inhibitors - Abstract
Guidelines summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously. A large number of Guidelines have been issued in recent years by the European Society of Cardiology (ESC) as well as by other societies and organizations. Because of the impact on clinical practice, quality criteria for development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC Web Site (http://www.escardio.org/guidelines-surveys/esc-guidelines/about/Pages/rules-writing.aspx). In brief, experts in the field are selected and undertake a comprehensive review of the published evidence for management and/or prevention of a given condition. A critical evaluation of diagnostic and therapeutic procedures is performed, including assessment of the risk–benefit ratio. Estimates of expected health outcomes for larger societies are included, where data exist. The level of evidence and the strength of recommendation of particular treatment options are weighed and graded according to pre-defined scales, as outlined in Tables 1 and 2 . View this table: Table 1 Classes of recommendations View this table: Table 2 Levels of evidence The experts of the writing panels have provided disclosure statements of all relationships they may have that might be perceived as real or potential sources of conflicts of interest. These disclosure forms are kept on file at the European Heart House, headquarters of the ESC. Any changes in conflict of interest that arise during the writing period must be notified to the ESC. The Task Force report received its entire financial support from …
- Published
- 2010